Loomis, Sayles & Company
VTYX

Loomis, Sayles & Company’s Ventyx Biosciences VTYX Stock Holding History

Loomis, Sayles & Company’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,257,973
Closed -$43.7M – 1052
2023
Q3 		$43.7M Buy
1,257,973
+259,736
+26% +$8.98M 0.08% 124
2023
Q2 		$32.7M Buy
+998,237
New +$34.4M 0.05% 175

Other funds holding VTYX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Loomis, Sayles & Company's VTYX Position: Q4 2023 in Review

Loomis, Sayles & Company sold out of Ventyx Biosciences (VTYX) in Q4 2023, closing a stake of 1,257,973 shares — an estimated $43.7M sold.

Loomis, Sayles & Company first reported a position in VTYX in Q2 2023 and held it in 2 quarters. The position peaked at $43.7M in Q3 2023. 121 funds tracked by Wall St. Rank hold VTYX as of Q4 2023.

  • Loomis, Sayles & Company reported no remaining Ventyx Biosciences position as of Q4 2023 after selling out during the quarter.
  • Loomis, Sayles & Company sold 1,257,973 Ventyx Biosciences shares in Q4 2023, an estimated $43.7M.
  • Loomis, Sayles & Company first reported a position in Ventyx Biosciences in Q2 2023 and held it in 2 quarters.
  • Loomis, Sayles & Company's Ventyx Biosciences position peaked at $43.7M in Q3 2023.
  • 121 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q4 2023.

Based on Loomis, Sayles & Company's 13F filing for Q4 2023, filed 13 Feb 2024.